Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Am J Pathol ; 182(3): 886-94, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23321322

RESUMEN

Chagas disease, caused by Trypanosoma cruzi, is an important cause of morbidity and mortality primarily resulting from cardiac dysfunction, although T. cruzi infection results in inflammation and cell destruction in many organs. We found that T. cruzi (Brazil strain) infection of mice results in pancreatic inflammation and parasitism within pancreatic ß-cells with apparent sparing of α cells and leads to the disruption of pancreatic islet architecture, ß-cell dysfunction, and surprisingly, hypoglycemia. Blood glucose and insulin levels were reduced in infected mice during acute infection and insulin levels remained low into the chronic phase. In response to the hypoglycemia, glucagon levels 30 days postinfection were elevated, indicating normal α-cell function. Administration of L-arginine and a ß-adrenergic receptor agonist (CL316, 243, respectively) resulted in a diminished insulin response during the acute and chronic phases. Insulin granules were docked, but the lack of insulin secretion suggested an inability of granules to fuse at the plasma membrane of pancreatic ß-cells. In the liver, there was a concomitant reduced expression of glucose-6-phosphatase mRNA and glucose production from pyruvate (pyruvate tolerance test), demonstrating defective hepatic gluconeogenesis as a cause for the T. cruzi-induced hypoglycemia, despite reduced insulin, but elevated glucagon levels. The data establishes a complex, multi-tissue relationship between T. cruzi infection, Chagas disease, and host glucose homeostasis.


Asunto(s)
Enfermedad de Chagas/metabolismo , Glucosa/metabolismo , Homeostasis , Tejido Adiposo Blanco/patología , Animales , Glucemia/metabolismo , Enfermedad de Chagas/sangre , Enfermedad de Chagas/parasitología , Enfermedad de Chagas/patología , Modelos Animales de Enfermedad , Técnica del Anticuerpo Fluorescente , Glucagón/sangre , Gluconeogénesis , Insulina/sangre , Hígado/metabolismo , Hígado/parasitología , Hígado/patología , Masculino , Ratones , Páncreas/parasitología , Páncreas/patología , Páncreas/ultraestructura , Trypanosoma cruzi/fisiología
2.
J Exp Med ; 204(4): 929-40, 2007 Apr 16.
Artículo en Inglés | MEDLINE | ID: mdl-17420269

RESUMEN

Chagas' disease is caused by infection with the parasite Trypanosoma cruzi. We report that infected, but not uninfected, human endothelial cells (ECs) released thromboxane A(2) (TXA(2)). Physical chromatography and liquid chromatography-tandem mass spectrometry revealed that TXA(2) is the predominant eicosanoid present in all life stages of T. cruzi. Parasite-derived TXA(2) accounts for up to 90% of the circulating levels of TXA(2) in infected wild-type mice, and perturbs host physiology. Mice in which the gene for the TXA(2) receptor (TP) has been deleted, exhibited higher mortality and more severe cardiac pathology and parasitism (fourfold) than WT mice after infection. Conversely, deletion of the TXA(2) synthase gene had no effect on survival or disease severity. TP expression on somatic cells, but not cells involved in either acquired or innate immunity, was the primary determinant of disease progression. The higher intracellular parasitism observed in TP-null ECs was ablated upon restoration of TP expression. We conclude that the host response to parasite-derived TXA(2) in T. cruzi infection is possibly an important determinant of mortality and parasitism. A deeper understanding of the role of TXA(2) may result in novel therapeutic targets for a disease with limited treatment options.


Asunto(s)
Enfermedad de Chagas/metabolismo , Enfermedad de Chagas/patología , Tromboxano A2/metabolismo , Trypanosoma cruzi/patogenicidad , Enfermedad Aguda , Animales , Células Cultivadas , Enfermedad de Chagas/genética , Enfermedad de Chagas/parasitología , Subunidades alfa de la Proteína de Unión al GTP Gq-G11/metabolismo , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores de Tromboxano A2 y Prostaglandina H2/metabolismo , Transducción de Señal , Tromboxano A2/deficiencia , Tromboxano A2/genética , Trypanosoma cruzi/fisiología
3.
Arterioscler Thromb Vasc Biol ; 30(6): 1159-65, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20299691

RESUMEN

OBJECTIVE: Adiponectin is an adipocyte-derived, secreted protein that is implicated in protection against a cluster of related metabolic disorders. Mice lacking adiponectin display impaired hepatic insulin sensitivity and respond only partially to peroxisome proliferator-activated receptor gamma agonists. Adiponectin has been associated with antiinflammatory and antiatherogenic properties; however, the direct involvement of adiponectin on the atherogenic process has not been studied. METHODS AND RESULTS: We crossed adiponectin knockout mice (Adn(-/-)) or mice with chronically elevated adiponectin levels (Adn(Tg)) into the low-density lipoprotein receptor-null (Ldlr(-/-)) and the apoliprotein E-null (Apoe(-/-)) mouse models. Adiponectin levels did not correlate with a suppression of the atherogenic process. Plaque volume in the aortic root, cholesterol accumulation in the aorta, and plaque morphology under various dietary conditions were not affected by circulating adiponectin levels. In light of the strong associations reported for adiponectin with cardiovascular disease in humans, the lack of a phenotype in gain- and loss-of-function studies in mice suggests a lack of causation for adiponectin in inhibiting the buildup of atherosclerotic lesions. CONCLUSIONS: These data indicate that the actions of adiponectin on the cardiovascular system are complex and multifaceted, with a minimal direct impact on atherosclerotic plaque formation in preclinical rodent models.


Asunto(s)
Enfermedades de la Aorta/metabolismo , Aterosclerosis/metabolismo , Acetatos/farmacología , Adiponectina/sangre , Adiponectina/deficiencia , Adiponectina/genética , Adiponectina/metabolismo , Animales , Enfermedades de la Aorta/sangre , Enfermedades de la Aorta/tratamiento farmacológico , Enfermedades de la Aorta/genética , Enfermedades de la Aorta/patología , Apolipoproteínas E/deficiencia , Apolipoproteínas E/genética , Aterosclerosis/sangre , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/genética , Aterosclerosis/patología , Colesterol/metabolismo , Modelos Animales de Enfermedad , Femenino , Genotipo , Indoles/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , PPAR gamma/agonistas , PPAR gamma/metabolismo , Fenotipo , Receptores de LDL/deficiencia , Receptores de LDL/genética , Factores de Tiempo
4.
J Infect Dis ; 202(7): 1104-13, 2010 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-20726767

RESUMEN

Mice carrying a defective leptin receptor gene (db/db mice) are metabolically challenged and upon infection with Trypanosoma cruzi (Brazil strain) suffer high mortality. In genetically modified db/db mice, (NSE-Rb db/db mice), central leptin signaling is reconstituted only in the brain, which is sufficient to correct the metabolic defects. NSE-Rb db/db mice were infected with T. cruzi to determine the impact of the lack of leptin signaling on infection in the absence of metabolic dysregulation. Parasitemia levels, mortality rates, and tissue parasitism were statistically significantly increased in infected db/db mice compared with those in infected NSE-Rb db/db and FVB wild-type mice. There was a reduction in fat mass and blood glucose level in infected db/db mice. Plasma levels of several cytokines and chemokines were statistically significantly increased in infected db/db mice compared with those in infected FVB and NSE-Rb db/db mice. These findings suggest that leptin resistance in individuals with obesity and diabetes mellitus may have adverse consequences in T. cruzi infection.


Asunto(s)
Enfermedad de Chagas/patología , Enfermedad de Chagas/parasitología , Receptores de Leptina/fisiología , Trypanosoma cruzi/patogenicidad , Tejido Adiposo/patología , Animales , Glucemia/análisis , Enfermedad de Chagas/mortalidad , Citocinas/sangre , Ratones , Parasitemia , Receptores de Leptina/deficiencia , Análisis de Supervivencia
5.
J Cell Biol ; 161(5): 861-74, 2003 Jun 09.
Artículo en Inglés | MEDLINE | ID: mdl-12796475

RESUMEN

Nuclear factor of activated T cell (NFAT) is a ubiquitous regulator involved in multiple biological processes. Here, we demonstrate that NFAT is temporally required in the developing atrial myocardium between embryonic day 14 and P0 (birth). Inhibition of NFAT activity by conditional expression of dominant-negative NFAT causes thinning of the atrial myocardium. The thin myocardium exhibits severe sarcomere disorganization and reduced expression of cardiac troponin-I (cTnI) and cardiac troponin-T (cTnT). Promoter analysis indicates that NFAT binds to and regulates transcription of the cTnI and the cTnT genes. Thus, regulation of cytoskeletal protein gene expression by NFAT may be important for the structural architecture of the developing atrial myocardium.


Asunto(s)
Proteínas de Unión al ADN/metabolismo , Regulación del Desarrollo de la Expresión Génica/genética , Atrios Cardíacos/anomalías , Atrios Cardíacos/crecimiento & desarrollo , Miocardio/metabolismo , Proteínas Nucleares , Factores de Transcripción/metabolismo , Transporte Activo de Núcleo Celular/genética , Animales , Animales Recién Nacidos , Sitios de Unión/genética , Núcleo Celular/genética , Proteínas de Unión al ADN/genética , Regulación hacia Abajo/genética , Feto , Genes Reguladores/genética , Atrios Cardíacos/metabolismo , Ratones , Ratones Transgénicos , Microscopía Electrónica , Mutación/genética , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Miocitos Cardíacos/ultraestructura , Factores de Transcripción NFATC , Regiones Promotoras Genéticas/genética , Sarcómeros/metabolismo , Sarcómeros/patología , Sarcómeros/ultraestructura , Factores de Transcripción/genética , Troponina I/biosíntesis , Troponina I/genética , Troponina T/biosíntesis , Troponina T/genética
6.
Arthritis Rheum ; 58(9): 2824-34, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18759321

RESUMEN

OBJECTIVE: This study was undertaken to determine whether BAFF blockade can be used to prevent or treat antiphospholipid syndrome in a mouse model. METHODS: Eight- and 12-week-old (NZW x BXSB)F(1) mice were treated with BAFF-R-Ig or TACI-Ig alone or in addition to a short course of CTLA-4Ig. Mice were monitored for thrombocytopenia and proteinuria. Sera were tested for anticardiolipin antibodies (aCL), BAFF levels, and levels of soluble vascular cell adhesion molecule and E-selectin. Mice were killed at 17, 22, or 32 weeks of age, and kidneys and hearts were subjected to histologic examination. Spleen cells were phenotyped and enzyme-linked immunospot assays for autoantibody-producing B cells were performed. RESULTS: Both BAFF-R-Ig and TACI-Ig prevented disease onset and significantly prolonged survival. Treated mice had significantly smaller spleens than controls, with fewer B cells and fewer activated and memory T cells. BAFF blockade did not prevent the development of aCL, and there was only a modest delay in the development of thrombocytopenia. However, treated mice had significantly less nephritis and myocardial infarcts than did controls. CONCLUSION: Our findings suggest that aCL are generated in the germinal center, which is relatively independent of BAFF. Effector function of antiplatelet antibodies was only modestly affected by BAFF blockade. In contrast, myocardial infarctions were prevented, suggesting that triggering of thromboses requires both autoantibodies and mediators of inflammation. Similarly, renal damage requires both immune complexes and effector cells. The dissociation between autoantibody production and inflammation that may occur with B cell-depleting therapies underscores the role of B cells as effector cells in the autoimmune response.


Asunto(s)
Síndrome Antifosfolípido/prevención & control , Autoanticuerpos/inmunología , Factor Activador de Células B/metabolismo , Animales , Síndrome Antifosfolípido/inmunología , Síndrome Antifosfolípido/metabolismo , Autoinmunidad/inmunología , Factor Activador de Células B/inmunología , Receptor del Factor Activador de Células B/antagonistas & inhibidores , Receptor del Factor Activador de Células B/inmunología , Linfocitos B/citología , Linfocitos B/inmunología , Linfocitos B/metabolismo , Cardiolipinas/inmunología , Cardiolipinas/metabolismo , Modelos Animales de Enfermedad , Selectina E/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Inmunohistoquímica , Estimación de Kaplan-Meier , Riñón/inmunología , Riñón/metabolismo , Masculino , Ratones , Miocardio/inmunología , Miocardio/metabolismo , Proteinuria/inmunología , Proteinuria/patología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Bazo/citología , Bazo/inmunología , Bazo/metabolismo , Coloración y Etiquetado , Estadísticas no Paramétricas , Molécula 1 de Adhesión Celular Vascular/metabolismo
7.
Diagn Microbiol Infect Dis ; 62(3): 333-5, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18691843

RESUMEN

Specific identification of Entamoeba histolytica in clinical specimens is an essential confirmatory diagnostic step in the management of amebiasis. Here, we report an unusual case of amebic colitis in a 20-year-old female immigrant from South China. The patient had experienced diarrhea, crampy abdominal pain, and fever for approximately 3 weeks prior to admission to hospital and had treated herself at home with metronidazole. On admission, stool microscopy and serology for E. histolytica were negative. Because the clinical findings raised the suspicion of Clostridium difficile fulminant colitis, she underwent a subtotal colectomy. Histopathology revealed flask-shaped ulcers characteristic of amebic colitis. Consequently, E. histolytica DNA was detected by a sensitive small-subunit rRNA polymerase chain reaction (PCR) from feces, and the patient was successfully treated for amebiasis with metronidazole. This case exemplifies the relative insensitivity of serologic tests for the diagnosis of intestinal amebiasis and the difficulties encountered in detecting the parasite antigen in a patient partially treated with metronidazole. We conclude that when the possibility of invasive intestinal amebiasis is suspected, detecting the parasite DNA directly in the stool sample by PCR using E. histolytica-specific primers may be an alternative, noninvasive, and reliable tool for the specific diagnosis of the disease.


Asunto(s)
Disentería Amebiana/diagnóstico , Entamoeba histolytica/aislamiento & purificación , Entamebiasis/diagnóstico , Genes de ARNr , Reacción en Cadena de la Polimerasa/métodos , Subunidades Ribosómicas Pequeñas/genética , Amebicidas/uso terapéutico , Animales , China/etnología , Disentería Amebiana/tratamiento farmacológico , Disentería Amebiana/cirugía , Entamoeba histolytica/genética , Entamebiasis/tratamiento farmacológico , Entamebiasis/cirugía , Ensayo de Inmunoadsorción Enzimática/métodos , Heces/parasitología , Femenino , Humanos , Metronidazol/uso terapéutico , ARN Protozoario/genética , Adulto Joven
8.
J Clin Invest ; 111(10): 1497-504, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12750399

RESUMEN

Heart failure is a common, lethal condition whose pathogenesis is poorly understood. Recent studies have identified low levels of myocyte apoptosis (80-250 myocytes per 10(5) nuclei) in failing human hearts. It remains unclear, however, whether this cell death is a coincidental finding, a protective process, or a causal component in pathogenesis. Using transgenic mice that express a conditionally active caspase exclusively in the myocardium, we demonstrate that very low levels of myocyte apoptosis (23 myocytes per 10(5) nuclei, compared with 1.5 myocytes per 10(5) nuclei in controls) are sufficient to cause a lethal, dilated cardiomyopathy. Interestingly, these levels are four- to tenfold lower than those observed in failing human hearts. Conversely, inhibition of cardiac myocyte death in this murine model largely prevents the development of cardiac dilation and contractile dysfunction, the hallmarks of heart failure. To our knowledge, these data provide the first direct evidence that myocyte apoptosis may be a causal mechanism of heart failure, and they suggest that inhibition of this cell death process may constitute the basis for novel therapies.


Asunto(s)
Apoptosis , Modelos Animales de Enfermedad , Insuficiencia Cardíaca/etiología , Miocitos Cardíacos/metabolismo , Tacrolimus/análogos & derivados , Animales , Caspasa 8 , Caspasa 9 , Caspasas/genética , Dimerización , Progresión de la Enfermedad , Activación Enzimática/efectos de los fármacos , Activadores de Enzimas/farmacología , Insuficiencia Cardíaca/metabolismo , Insuficiencia Cardíaca/patología , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Miocardio/metabolismo , Miocardio/patología , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/patología , Especificidad de Órganos/genética , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/efectos de los fármacos , Proteínas Recombinantes de Fusión/genética , Tacrolimus/farmacología , Proteínas de Unión a Tacrolimus/genética , Transgenes
9.
Circulation ; 108(19): 2387-92, 2003 Nov 11.
Artículo en Inglés | MEDLINE | ID: mdl-14568904

RESUMEN

BACKGROUND: The timely reperfusion of ischemic myocardium limits infarction, but components of reperfusion, such as inflammation, may be injurious. The chemokine receptor CXCR2 mediates neutrophil chemotaxis. CXCR2 activation also inhibits hypoxia-induced death of isolated cardiac myocytes. This study assesses whether CXCR2 mediates protection in the intact heart and, if so, the magnitude of this protection relative to CXCR2-mediated chemotaxis of potentially damaging inflammatory cells. METHODS AND RESULTS: After ischemia-reperfusion in vivo, CXCR2-/- mice exhibited infarcts that were 50.5% smaller (P<0.05) with 44.3% fewer inflammatory cells (P<0.05) than wild type mice. These data suggest that in this model, CXCR2-mediated chemotaxis may be important in myocardial cell death. To isolate the role of CXCR2 specifically on blood cells, adoptive transfer experiments were performed. After ischemia-reperfusion, infarcts were 53.4% smaller (P<0.05) and contained 65.0% fewer inflammatory cells (P<0.05) in lethally irradiated wild type mice reconstituted with CXCR2-/- compared with wild type bone marrow. Thus, CXCR2 on blood cells is important in myocardial damage, most likely because of CXCR2-mediated chemotaxis. To unmask whether CXCR2 mediates direct myocardial protection in the intact heart, wild type and CXCR2-/- hearts were studied in the absence of blood using Langendorff preparations. In this case, infarcts were 19.7% larger in CXCR2-/- than wild type hearts (P<0.05), revealing a novel CXCR2-mediated cardioprotective effect. CONCLUSIONS: CXCR2 exerts opposing effects on myocardial viability during ischemia-reperfusion with recruitment of damaging inflammatory cells predominant over direct tissue protection.


Asunto(s)
Quimiotaxis de Leucocito/fisiología , Isquemia Miocárdica/patología , Daño por Reperfusión Miocárdica/patología , Receptores de Interleucina-8B/fisiología , Traslado Adoptivo , Animales , Células de la Médula Ósea/metabolismo , Trasplante de Médula Ósea , Muerte Celular , Hipoxia de la Célula , Inflamación , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Infarto del Miocardio/inmunología , Infarto del Miocardio/patología , Isquemia Miocárdica/inmunología , Daño por Reperfusión Miocárdica/inmunología , Neutrófilos/efectos de los fármacos , Neutrófilos/fisiología , Especificidad de Órganos , Quimera por Radiación
10.
Magn Reson Imaging ; 23(1): 61-8, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15733789

RESUMEN

Caveolin-1 and caveolin-3 are expressed in the mammalian heart. Mice deficient in caveolin 1 or 3 exhibit cardiac abnormalities including left ventricular hypertrophy and reduced fractional shortening. Cardiac imaging technologies such as transthoracic echocardiography and cardiac-gated magnetic resonance imaging (MRI) are effective tools for the study of left ventricular morphology and function in mice; however, there has not been widespread use of these technologies in studies of right ventricular morphology. In particular, right ventricular wall thickness has been difficult to assess using cardiac imaging technologies. We report here the use of centerline analysis of cardiac-gated MR images to more accurately determine right ventricular wall thickness in the mouse heart. Right ventricular wall thickness was evaluated in Cav-1 null, Cav-3 null and Cav-1/3 null mice, as well as wild-type control mice. Using this technique, we find that caveolin null mice exhibit significant thickening of the right ventricular wall as compared with age-matched wild-type controls. Interestingly, right ventricular wall thickening is greatest in the Cav-1/3 null mice. Furthermore, significant right ventricular wall thickening is also seen in the Cav-1 null mice. Histological analyses revealed right ventricular hypertrophy consistent with the imaging results. These studies demonstrate the utility of MRI in determining right ventricular wall thickness and underscore the severity of the right ventricular hypertrophy in caveolin null mice.


Asunto(s)
Cardiomiopatía Hipertrófica/diagnóstico , Cardiomiopatía Hipertrófica/fisiopatología , Caveolinas/genética , Ventrículos Cardíacos/fisiopatología , Imagen por Resonancia Magnética/métodos , Animales , Caveolina 1 , Caveolina 3 , Ratones
11.
Int J Parasitol ; 32(2): 207-15, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11812498

RESUMEN

Verapamil has been shown to attenuate the extent of myocardial injury in murine models of chronic Trypanosoma cruzi infection. Infected mice treated with verapamil have significantly lower myocardial expression of inducible nitric oxide synthase and cytokines and substantially less inflammatory infiltrate and myocyte necrosis at necropsy. In the present study, we examined the cardiac structural and functional correlates of verapamil treatment in CD1 mice infected with the Brazil strain of T. cruzi using serial transthoracic echocardiography. There were four groups: uninfected- untreated control, uninfected-verapamil-treated, infected-untreated control, and infected-verapamil-treated. Verapamil was given in drinking water (1 gm/l) continuously from the day of infection for a total of 120 days. Mice were evaluated at baseline, 40 and 150 days p.i. Mice in the untreated-infected group compared with the mice in the infected-verapamil-treated group showed thinning of the left ventricular wall (0.84 +/- 0.02-vs-0.92 +/- 0.04, P<0.05 mm), increase in the left ventricular end-diastolic diameter (3.27 +/- 0.15-vs-2.74 +/- 0.05 mm, P<0.05) and reduction in percent fractional shortening (37 +/- 2-vs-53 +/- 4%, P<0.05). No differences in these parameters were noted among mice in the uninfected-untreated and uninfected-verapamil-treated groups. Furthermore, right ventricular dilation was more severe in mice from the infected-untreated group as compared with those in the infected- verapamil-treated group (visual grade 1.9 +/- 0.4-vs-1.0 +/- 0.2, P<0.05). At necropsy, the extent of myocardial injury, as determined histologically, was significantly greater in the infected-untreated mice. These data provide cardiac structural and functional correlates for the previously observed cardioprotective effects of verapamil in chronic chagasic cardiomyopathy.


Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Cardiotónicos/farmacología , Enfermedad de Chagas/tratamiento farmacológico , Miocardio/patología , Trypanosoma cruzi/metabolismo , Función Ventricular/efectos de los fármacos , Verapamilo/farmacología , Animales , Bloqueadores de los Canales de Calcio/uso terapéutico , Cardiotónicos/uso terapéutico , Enfermedad de Chagas/diagnóstico por imagen , Enfermedad de Chagas/patología , Enfermedad de Chagas/fisiopatología , Colágeno/análisis , Colágeno/biosíntesis , Modelos Animales de Enfermedad , Ecocardiografía , Histocitoquímica , Masculino , Ratones , Trypanosoma cruzi/efectos de los fármacos , Verapamilo/uso terapéutico
12.
Int J Parasitol ; 32(7): 897-905, 2002 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-12062561

RESUMEN

Chagas' disease, caused by Trypanosoma cruzi, is associated with myocarditis and expression of myocardial cytokines and inducible nitric oxide synthase (NOS2). To assess the functional significance of NOS2 in murine Chagas' disease, we infected NOS2 knockout (NOS2(-/-)) and C57BL/6x129sv (wild type) mice with the Tulahuen strain of T. cruzi. Serial transthoracic echocardiography was performed to assess the progression of left and right ventricular dysfunction in infected mice. Uninfected wild type and NOS2(-/-) mice served as controls. At day 10 post-infection (p.i.), infected wild type mice had larger left ventricular end-diastolic diameter (2.52+/-0.14-vs-2.11+/-0.06 mm, P<0.02) and right ventricle (0.6+/-0.2-vs-0 visual grade, P<0.02) as compared with uninfected wild type mice. At day 19 p.i., compared with uninfected controls, infected wild type mice had larger left ventricular end-diastolic diameter (3.30+/-0.29-vs-2.11+/-0.07 mm), left ventricular end-systolic diameter (1.86+/-0.29-vs-0.88+/-0.05 mm), right ventricle (1.6+/-0.2-vs-0 visual grade), lower heart rate (413+/-27-vs-557+/-25 beats per min), left ventricular relative wall thickness (0.44+/-0.05-vs-0.64+/-0.03) and fractional shortening (45+/-4-vs-57+/-2%) [P<0.05 for all]. In contrast, no differences in left ventricular end-diastolic diameter or fractional shortening were noted among infected and uninfected NOS2(-/-) mice at day 19 p.i. Compared with uninfected controls, infected NOS2(-/-) mice had significantly lower heart rate (272+/-23-vs-512+/-31 beats per min, P<0.01) and larger right ventricle (0.6+/-0.2-vs-0, P<0.05 visual grade). The magnitude of right ventricular dilation in NOS2(-/-) mice was less than that observed in infected wild type mice. At necropsy, the heart weight was greater (129+/-16-vs-109+/-7 mg, P=0.02) and myocardial inflammation more severe in infected wild type compared with infected NOS2(-/-) mice. Myocardial interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha, and interferon-gamma were induced in all infected mice. These data indicate that nitric oxide derived from NOS2 plays an important role in the development and progression of ventricular dilation and systolic dysfunction in acute murine chagasic myocarditis caused by infection with the Tulahuen strain.


Asunto(s)
Enfermedad de Chagas/enzimología , Miocarditis/enzimología , Óxido Nítrico Sintasa/metabolismo , Trypanosoma cruzi/enzimología , Animales , Enfermedad de Chagas/parasitología , Enfermedad de Chagas/patología , Citocinas/análisis , Citocinas/biosíntesis , Electrocardiografía , Regulación de la Expresión Génica/genética , Histocitoquímica , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Miocarditis/parasitología , Miocarditis/patología , Óxido Nítrico Sintasa de Tipo II , Parasitemia , ARN Protozoario/química , ARN Protozoario/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Trypanosoma cruzi/genética , Trypanosoma cruzi/metabolismo
13.
Int J Parasitol ; 32(12): 1497-506, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12392915

RESUMEN

Chagas' disease is an important cause of cardiomyopathy. Endothelin-1, a vasoactive peptide has been implicated in the pathogenesis of chagasic cardiomyopathy. C57BL/6 x 129sv and CD1 mice were thus, infected with trypomastigotes of Trypanosoma cruzi (Brazil strain) and these infected mice were compared with infected mice treated with phosphoramidon. This compound inhibits endothelin-converting enzyme and neutral endopeptidases and does not affect the growth of the parasite in culture. Phosphoramidon was given in a dose of 10mg/kg for the initial 15 days post-infection None of the C57Bl/6 x 129sv mice died as a result of infection. However, there was marked myocardial inflammation and fibrosis in infected, untreated mice. The hearts of the infected, phosphoramidon-treated mice showed significantly less pathology. Cardiac magnetic resonance imaging of infected mice revealed right ventricular dilation that was less severe in those treated with phosphoramidon. Phosphoramidon-treated CD1 mice survived the acute infection. Transthoracic echocardiography demonstrated left ventricular dilation and reduced percent fractional shortening and relative wall thickness. These alterations were also attenuated as a result of phosphoramidon treatment. These data suggest that endothelin-1 contributes to the pathogenesis of chagasic cardiomyopathy and interventions that inhibit the synthesis of endothelin-1 and/or neutral endopeptidase might have a protective effect on myocardial structure and function in murine Chagas' disease.


Asunto(s)
Cardiomiopatía Chagásica/tratamiento farmacológico , Cardiomiopatía Chagásica/fisiopatología , Glicopéptidos/farmacología , Corazón/efectos de los fármacos , Corazón/fisiopatología , Miocardio/patología , Inhibidores de Proteasas/farmacología , Animales , Cardiomiopatía Chagásica/parasitología , Cardiomiopatía Chagásica/patología , Modelos Animales de Enfermedad , Ecocardiografía , Regulación de la Expresión Génica/efectos de los fármacos , Glicopéptidos/uso terapéutico , Corazón/parasitología , Imagen por Resonancia Magnética , Masculino , Ratones , Ratones Endogámicos , Miocardio/química , Miocardio/enzimología , Miocardio/metabolismo , Inhibidores de Proteasas/uso terapéutico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Trypanosoma cruzi
14.
Autoimmunity ; 37(6-7): 445-51, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15621570

RESUMEN

NZW "x" BXSB F1 mice develop SLE that is associated with an anti-phospholipid syndrome characterized by anti-cardiolipin antibodies, thrombocytopenia and small coronary artery thrombosis. This syndrome is immune mediated and, dependent, on CD4+T cells. To determine whether disease in these mice can be treated with blockade of T cell costimulation we treated them with the CD28 antagonist CTLA4Ig at 9 or 12 weeks of age. CTLA4Ig completely prevented both SLE nephritis and myocardial infarcts if it was given at 9 weeks of age, before anti-cardiolipin antibodies could be detected in the serum and prevented both B cell expansion and activation and the development of peripheral monocytosis. If treatment was delayed until 12 weeks of age after cardiolipin antibodies had arisen but before the onset of clinical disease, CTLA4Ig had very little effect on disease progression. These findings indicate that CD4+T cell activation through CD28 is critical for disease initiation in this model but plays little role in disease progression or tissue damage. These findings have relevance to the treatment of anti-phospholipid syndrome in humans.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Síndrome Antifosfolípido/prevención & control , Inmunoconjugados/farmacología , Abatacept , Animales , Síndrome Antifosfolípido/tratamiento farmacológico , Síndrome Antifosfolípido/inmunología , Modelos Animales de Enfermedad , Femenino , Citometría de Flujo , Corazón/efectos de los fármacos , Inmunoconjugados/sangre , Inmunoconjugados/inmunología , Riñón/efectos de los fármacos , Riñón/patología , Masculino , Ratones , Miocardio/patología , Factores de Tiempo
15.
Echocardiography ; 15(3): 243-256, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11175036

RESUMEN

This article examines the transesophageal echocardiographic assessment of the left atrial appendage anatomy and function in individuals without significant structural heart disease and in those with atrial fibrillation with or without cardioembolism or mitral valve stenosis. We also summarize the available data in the usefulness of transesophageal echocardiographic studies in patients undergoing cardioversion for atrial fibrillation and percutaneous balloon valvuloplasty for mitral stenosis. Also, potential limitations and ongoing developments in the use of transesophageal echocardiography in the assessment of the left atrial appendage are outlined, and recommendations are given for the uniform reporting of quantitative data.

16.
PLoS Negl Trop Dis ; 8(10): e3118, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25275627

RESUMEN

BACKGROUND: Trypanosoma cruzi, the causative agent of Chagas disease, has high affinity for lipoproteins and adipose tissue. Infection results in myocarditis, fat loss and alterations in lipid homeostasis. This study was aimed at analyzing the effect of high fat diet (HFD) on regulating acute T. cruzi infection-induced myocarditis and to evaluate the effect of HFD on lipid metabolism in adipose tissue and heart during acute T. cruzi infection. METHODOLOGY/PRINCIPAL FINDINGS: CD1 mice were infected with T. cruzi (Brazil strain) and fed either a regular control diet (RD) or HFD for 35 days following infection. Serum lipid profile, tissue cholesterol levels, blood parasitemia, and tissue parasite load were analyzed to evaluate the effect of diet on infection. MicroPET and MRI analysis were performed to examine the morphological and functional status of the heart during acute infection. qPCR and immunoblot analysis were carried out to analyze the effect of diet on the genes involved in the host lipid metabolism during infection. Oil red O staining of the adipose tissue demonstrated reduced lipolysis in HFD compared to RD fed mice. HFD reduced mortality, parasitemia and cardiac parasite load, but increased parasite load in adipocytes. HFD decreased lipolysis during acute infection. Both qPCR and protein analysis demonstrated alterations in lipid metabolic pathways in adipose tissue and heart in RD fed mice, which were further modulated by HFD. Both microPET and MRI analyses demonstrated changes in infected RD murine hearts which were ameliorated by HFD. CONCLUSION/SIGNIFICANCE: These studies indicate that Chagasic cardiomyopathy is associated with a cardiac lipidpathy and that both cardiac lipotoxicity and adipose tissue play a role in the pathogenesis of Chagas disease. HFD protected mice from T. cruzi infection-induced myocardial damage most likely due to the effects of HFD on both adipogenesis and T. cruzi infection-induced cardiac lipidopathy.


Asunto(s)
Cardiomiopatía Chagásica/metabolismo , Miocarditis/metabolismo , Adipogénesis , Tejido Adiposo Blanco/metabolismo , Animales , Brasil , Cardiomiopatía Chagásica/parasitología , Cardiomiopatía Chagásica/patología , LDL-Colesterol/sangre , Dieta Alta en Grasa , Metabolismo de los Lípidos , Masculino , Ratones , Ratones Endogámicos C3H , Miocarditis/parasitología , Miocarditis/patología , Miocardio/metabolismo , Miocardio/patología
17.
Semin Immunopathol ; 34(6): 753-70, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23076807

RESUMEN

Chagas disease caused by Trypanosoma cruzi remains an important neglected tropical disease and a cause of significant morbidity and mortality. No longer confined to endemic areas of Latin America, it is now found in non-endemic areas due to immigration. The parasite may persist in any tissue, but in recent years, there has been increased recognition of adipose tissue both as an early target of infection and a reservoir of chronic infection. The major complications of this disease are cardiomyopathy and megasyndromes involving the gastrointestinal tract. The pathogenesis of Chagas disease is complex and multifactorial involving many interactive pathways. The significance of innate immunity, including the contributions of cytokines, chemokines, reactive oxygen species, and oxidative stress, has been emphasized. The role of the components of the eicosanoid pathway such as thromboxane A(2) and the lipoxins has been demonstrated to have profound effects as both pro- and anti-inflammatory factors. Additionally, we discuss the vasoconstrictive actions of thromboxane A(2) and endothelin-1 in Chagas disease. Human immunity to T. cruzi infection and its role in pathogen control and disease progression have not been fully investigated. However, recently, it was demonstrated that a reduction in the anti-inflammatory cytokine IL-10 was associated with clinically significant chronic chagasic cardiomyopathy.


Asunto(s)
Enfermedad de Chagas/inmunología , Trypanosoma cruzi/inmunología , Inmunidad Adaptativa , Animales , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/patología , Humanos , Inmunidad Innata , Estadios del Ciclo de Vida , Trypanosoma cruzi/crecimiento & desarrollo
18.
Adv Parasitol ; 76: 83-99, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21884888

RESUMEN

The cardiovascular manifestations of Chagas disease are well known. However, the contribution of the vasculature and specifically the microvasculature has received little attention. This chapter reviews the evidence supporting the notion that alterations in the microvasculature especially in the heart contribute to the pathogenesis of chagasic cardiomyopathy. These data may also be important in understanding the contributions of the microvasculature in the aetiologies of other cardiomyopathies. The role of endothelin-1 and of thromboxane A(2) vascular spasm and platelet aggregation is also discussed. Further, these observations may provide target(s) for intervention.


Asunto(s)
Vasos Sanguíneos/patología , Vasos Sanguíneos/parasitología , Cardiomiopatía Chagásica/patología , Cardiomiopatía Chagásica/parasitología , Animales , Perros , Endotelina-1/metabolismo , Humanos , Ratones , Agregación Plaquetaria , Tromboxano A2/metabolismo
19.
PLoS One ; 6(2): e16959, 2011 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-21347238

RESUMEN

Chagas disease, caused by infection with Trypanosoma cruzi, is an important cause of cardiovascular disease. It is increasingly clear that parasite-derived prostaglandins potently modulate host response and disease progression. Here, we report that treatment of experimental T. cruzi infection (Brazil strain) beginning 5 days post infection (dpi) with aspirin (ASA) increased mortality (2-fold) and parasitemia (12-fold). However, there were no differences regarding histopathology or cardiac structure or function. Delayed treatment with ASA (20 mg/kg) beginning 60 dpi did not increase parasitemia or mortality but improved ejection fraction. ASA treatment diminished the profile of parasite- and host-derived circulating prostaglandins in infected mice. To distinguish the effects of ASA on the parasite and host bio-synthetic pathways we infected cyclooxygenase-1 (COX-1) null mice with the Brazil-strain of T. cruzi. Infected COX-1 null mice displayed a reduction in circulating levels of thromboxane (TX)A(2) and prostaglandin (PG)F(2α). Parasitemia was increased in COX-1 null mice compared with parasitemia and mortality in ASA-treated infected mice indicating the effects of ASA on mortality potentially had little to do with inhibition of prostaglandin metabolism. Expression of SOCS-2 was enhanced, and TRAF6 and TNFα reduced, in the spleens of infected ASA-treated mice. Ablation of the initial innate response to infection may cause the increased mortality in ASA-treated mice as the host likely succumbs more quickly without the initiation of the "cytokine storm" during acute infection. We conclude that ASA, through both COX inhibition and other "off-target" effects, modulates the progression of acute and chronic Chagas disease. Thus, eicosanoids present during acute infection may act as immunomodulators aiding the transition to and maintenance of the chronic phase of the disease. A deeper understanding of the mechanism of ASA action may provide clues to the differences between host response in the acute and chronic T. cruzi infection.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Aspirina/farmacología , Enfermedad de Chagas/tratamiento farmacológico , Trypanosoma cruzi/patogenicidad , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Aspirina/uso terapéutico , Enfermedad de Chagas/metabolismo , Enfermedad de Chagas/parasitología , Enfermedad de Chagas/fisiopatología , Enfermedad Crónica , Ciclooxigenasa 1/deficiencia , Ciclooxigenasa 1/genética , Citocinas/metabolismo , Eicosanoides/biosíntesis , Eliminación de Gen , Masculino , Ratones , Parasitemia/tratamiento farmacológico , Parasitemia/metabolismo , Parasitemia/parasitología , Parasitemia/fisiopatología , Volumen Sistólico/efectos de los fármacos , Tromboxano-A Sintasa/deficiencia , Tromboxano-A Sintasa/genética , Factores de Tiempo , Trypanosoma cruzi/efectos de los fármacos
20.
Arthritis Rheum ; 60(4): 1096-101, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19333924

RESUMEN

OBJECTIVE: Male (NZW x BXSB)F(1) mice develop antiphospholipid syndrome (APS) and proliferative glomerulonephritis that is markedly accelerated by the Yaa locus encoding an extra copy of Tlr7. Female (NZW x BXSB)F(1) mice with only 1 active copy of Tlr7 develop late-onset glomerulonephritis but not APS. Because a major function of Toll-like receptor 7 is to induce type I interferons (IFNs), our goal was to determine whether IFNalpha can induce or accelerate the manifestations of systemic lupus erythematosus (SLE) in female (NZW x BXSB)F(1) mice. METHODS: Eight-week-old female (NZW x BXSB)F(1) mice were injected with a single dose of adenovirus expressing IFNalpha. Mice were monitored for the development of thrombocytopenia and proteinuria. Sera were tested for anticardiolipin and anti-Sm/RNP antibodies. Mice were killed at 17 or 22 weeks of age, and their kidneys and hearts were examined histologically and by immunohistochemistry. Spleen cells were phenotyped, and enzyme-linked immunospot assays for autoantibody-producing B cells were performed. RESULTS: IFNalpha markedly accelerated nephritis and death in female (NZW x BXSB)F(1) mice. A significant increase in spleen cell numbers associated with a striking increase in the number of activated B and T cells was observed. Marginal-zone B cells were retained. IFNalpha-induced increased titers of autoantibodies were observed, but thrombocytopenia was not observed. Cardiac damage was milder than that in male mice. CONCLUSION: IFNalpha accelerates the development of renal inflammatory disease in female (NZW x BXSB)F(1) mice but induces only mild APS and does not induce thrombocytopenia. The effect of IFNalpha on SLE disease manifestations is strain dependent. These findings are relevant to our understanding of the physiologic significance of the IFN signature.


Asunto(s)
Modelos Animales de Enfermedad , Interferón-alfa/genética , Nefritis Lúpica/genética , Glicoproteínas de Membrana/genética , Ratones Mutantes , Receptor Toll-Like 7/genética , Adenoviridae/genética , Animales , Síndrome Antifosfolípido/genética , Síndrome Antifosfolípido/inmunología , Síndrome Antifosfolípido/mortalidad , Linfocitos B/citología , Femenino , Dosificación de Gen , Nefritis Lúpica/inmunología , Nefritis Lúpica/mortalidad , Glicoproteínas de Membrana/inmunología , Ratones , Ratones Endogámicos , Fenotipo , Recuento de Plaquetas , Proteinuria/genética , Proteinuria/inmunología , Proteinuria/mortalidad , Índice de Severidad de la Enfermedad , Especificidad de la Especie , Bazo/citología , Receptor Toll-Like 7/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA